 |
인쇄하기
취소
|
New recombinant antihemophilic factor approved
Green Cross Corporation said on September 3 that the Korea Food and Drug Administration approved its new recombinant DNA-derived clotting factor to treat people with hemophilia A.
This new antihemophilic human factor VIII product is the one produced without using additives derived from human or animal blood in the manufacturing process, according to company officials.
This advancement pr...
This new antihemophilic human factor VIII product is the one produced without using additives derived from human or animal blood in the manufacturing process, according to company officials.
This advancement pr...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.